A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 11, 2012, Pages 1646-1653

  Gao, Mingming ^a   Jin, Yuhao ^a   Tong, Yue ^a   Tian, Hong ^a   Gao, Xiangdong ^a   Yao, Wenbing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

diabetes; exendin 4; GLP 1; incretin; PEGylation

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; PEGYLATED EXENDIN 4 DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CONFORMATION; DRUG CONJUGATION; DRUG DESIGN; DRUG HALF LIFE; DRUG PURITY; IN VIVO STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; RAT; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG DELIVERY SYSTEMS; HALF-LIFE; HYPOGLYCEMIC AGENTS; MALE; MICE; PEPTIDES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; VENOMS;

EID: 84867571552     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01545.x     Document Type: Article

References (25)

1. Holst JJ,. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 4: 1409-1439.
2. Drucker DJ, Nauck MA,. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 9548: 1696-1705.
3. Nielsen LL,. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 2005; 10: 703-710.
4. Nielsen LL, et al,. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 2: 77-88.
5. Simonsen L, et al,. Exendin-4, but not glucagon-like peptide-1, is cleared solely by the kidney in anaesthetized pigs. Diabetologia 2006; 49: 706-712.
6. Parkes D, et al,. Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Dev Res 2001; 4: 260-267.
7. Bloom SR, et al,. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 1: E155-E161.
8. Veronese FM, Mero A,. The impact of PEGylation on biological therapies. BioDrugs 2008; 5: 315-329.
9. Rodriguez-Martinez JA, et al,. Prevention of benzyl alcohol-induced aggregation of chymotrypsinogen by PEGylation. J Pharm Pharmacol 2011; 6: 800-805.
10. Tong Y, et al,. Characterization of a monoPEG20000-Endostar. Int J Biol Macromol 2010; 3: 331-336.
11. Gao M, et al,. Expression, purification, and C-terminal site-specific PEGylation of cysteine-mutated glucagon-like peptide-1. Appl Biochem Biotechnol 2010; 1: 155-165.
12. Ma C, et al,. Intein-mediated expression and purification of an analog of glucagon-like peptide-1 in Escherichia coli. Protein Pept Lett 2010; 10: 1245-1250.
13. Gao M, et al,. Production and purification of an analog of glucagon-like peptide-1 by auto-induction and on-column cleavage in Escherichia coli. World J Microb Biot 2010; 9: 1675-1682.
14. Zhou J, et al,. Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris. Eur J Pharm Biopharm 2009; 72: 412-417.
15. Shechter Y, et al,. Reversible pegylation of insulin facilitates its prolonged action in vivo. Eur J Pharm Biopharm 2008; 1: 19-28.
16. Mueller C, et al,. Tryptophan-mPEGs: novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation. Eur J Pharm Biopharm 2011; 79: 646-657.
17. Tsubery H, et al,. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J Biol Chem 2004; 37: 38118-38124.
18. Kim TH, et al,. Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics. Bioconjug Chem 2011; 4: 625-632.
19. Youn YS, et al,. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol 2007; 1: 84-93.
20. Donnelly D,. The Structure and Function of the Glucagon-Like Peptide-1 Receptor and Its Ligands. Br J Pharmacol 2012; 166: 27-41.
21. Fee CJ, Van Alstine JA,. PEG-proteins: reaction engineering and separation issues. Chem Eng Sci 2006; 3: 924-939.
22. Plesner B, et al,. Effects of PEG size on structure, function and stability of PEGylated BSA. Eur J Pharm Biopharm 2011; 2: 399-405.
23. Weyer KA, et al,. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 2003; 1: 78-87.
24. Mcevoy RC, et al,. Multiple Low-Dose Streptozotocin-Induced Diabetes in the Mouse-Evidence for Stimulation of a Cyto-Toxic Cellular Immune-Response against an Insulin-Producing Beta-Cell Line. J Clin Invest 1984; 3: 715-722.
25. Konrad RJ, et al,. The potential mechanism of the diabetogenic action of streptozotocin: inhibition of pancreatic beta-cell O-GlcNAc-selective N-acetyl-beta-D-glucosaminidase. Biochem J 2001; 356: 31-41.